ORIC Pharma

$4.63 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About ORIC Pharma

ORIC Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by overcoming resistance in cancer. The Company is focused on developing a diverse pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its experience within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. Its lead product candidate is ORIC-101. The Company’s ORIC-101 is a potent and selective small-molecule antagonist of the glucocorticoid receptor (GR), which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. The Company’s second product candidate, ORIC-533, is an orally bioavailable, small-molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy-and immunotherapy-based treatment regimens. Its third product candidate, ORIC-944, being developed for prostate cancer.

Stock Analysis

last close $4.71
1-mo return 10.3%
3-mo return 67.6%
avg daily vol. 166.54T
52-week high 26.7
52-week low 2.62
market cap. $191M
forward pe -
annual div. -
roe -32.3%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 84.9%
baraka

Subscribe now for daily local and international financial news

Subscribe